{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:02:27Z","timestamp":1785301347138,"version":"3.55.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>T-cell lymphomas show global variation, but research in Latin America remains limited. The main outcome This study aimed to determine, subtype distribution frequency, treatment, and overall survival of T-cell lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of 101 patients with mature T\/NK-cell neoplasms (2008\u20132025). Survival (OS and PFS) was analyzed using Kaplan\u2013Meier estimates and Cox models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median age was 58 years. PTCL-NOS (31.7%), anaplastic large cell lymphoma (20.8%), and extranodal NK\/T-cell lymphoma (18.8%) were the most frequent subtypes. The 36-month OS was 57.8% and PFS was 42.1%. Significant prognostic heterogeneity was observed, with anaplastic large cell lymphoma showing the best and T-prolymphocytic leukemia the poorest outcomes. In multivariable analysis, ECOG status \u22652 independently predicted higher mortality (HR\u00a0=\u00a02.73, p&amp;lt;0.001), while low LDH levels reduced risk (HR: 0.22; 95% CI: 0.08\u20130.61; p = 0.003).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings highlight the marked clinical heterogeneity of T-cell lymphomas and validate the prognostic value of ECOG and LDH in Latin America.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1898102","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:34:33Z","timestamp":1785299673000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival analysis and prognostic factors of mature T-cell and natural killer\/T-cell neoplasms in Colombian patients from 2008-2025"],"prefix":"10.3389","volume":"16","author":[{"given":"Juan F.","family":"Combariza-Vallejo","sequence":"first","affiliation":[{"name":"Cl\u00ednica Colsanitas, Cl\u00ednica Universitaria Colombia","place":["Bogot\u00e1, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Orduz-Rodriguez","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Colsanitas, Laboratorio cl\u00ednico y de patolog\u00eda","place":["Bogot\u00e1, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Gomez-Lopera","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Colsanitas, Laboratorio cl\u00ednico y de patolog\u00eda","place":["Bogot\u00e1, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia C.","family":"Colmenares-Mejia","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Universitaria Sanitas","place":["Bogot\u00e1, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Moreno-Martinez","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Colsanitas, Laboratorio cl\u00ednico y de patolog\u00eda","place":["Bogot\u00e1, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana J.","family":"Salazar-Vargas","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Colsanitas, Laboratorio cl\u00ednico y de patolog\u00eda","place":["Bogot\u00e1, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Godoy-Corredor","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Colsanitas, Laboratorio cl\u00ednico y de patolog\u00eda","place":["Bogot\u00e1, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Arturo","family":"Isaza-Ruget","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Colsanitas, Laboratorio cl\u00ednico y de patolog\u00eda","place":["Bogot\u00e1, Colombia"]},{"name":"Fundaci\u00f3n Universitaria Sanitas","place":["Bogot\u00e1, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1068662","article-title":"Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer\/T-cell lymphoma","volume":"14","author":"Yap","year":"2023","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s10147-016-1045-2","article-title":"T-cell lymphomas, a challenging disease: types, treatments, and future","volume":"22","author":"Ma","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.12688\/f1000research.12573.1","article-title":"Recent advances in understanding and managing T-cell lymphoma","volume":"6","author":"Yi","year":"2017","journal-title":"F1000Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2301-7","article-title":"General features and epidemiology of lymphoma in Colombia. A multicentric study","volume":"94","author":"Combariza","year":"2015","journal-title":"Ann Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1647777","article-title":"Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic\/dendritic cell neoplasms","volume":"12","author":"Satou","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","year":"2008","journal-title":"JCO"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2016.05.008","article-title":"The burden of non-Hodgkin lymphoma in Central and South America","volume":"44","author":"Diumenjo","year":"2016","journal-title":"Cancer Epidemiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.863269","article-title":"Epidemiological characteristics of peripheral T-cell lymphoma: A population-based study","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1099265","article-title":"Classification and challenges in the histopathological diagnosis of peripheral T-cell lymphomas, emphasis on the WHO-HAEM5 updates","volume":"12","author":"Murga-Zamalloa","year":"2022","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0524","article-title":"Recent advances in the treatment of peripheral T-cell lymphoma","volume":"23","author":"Laribi","year":"2018","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T\u2010cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2545927","article-title":"Relapsed and refractory peripheral T-cell lymphoma; treatment, challenges and future perspectives","volume":"66","author":"Meeuwes","year":"2025","journal-title":"Leukemia Lymphoma"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2540437","article-title":"Outcomes of relapsed\/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents","volume":"66","author":"Tolu","year":"2025","journal-title":"Leukemia Lymphoma"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-20-0228","article-title":"Linking environmental exposures to molecular pathogenesis in non-hodgkin lymphoma subtypes","volume":"29","author":"Moubadder","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1186\/s12935-021-02391-z","article-title":"Prognostic significance of the neutrophil-to-lymphocyte ratio in peripheral T-cell lymphoma: a meta-analysis","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01042-y","article-title":"Progression-free survival at 24 months and subsequent survival of patients with extranodal NK\/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study","volume":"35","author":"Yang","year":"2021","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"JCO"},{"key":"B20","volume-title":"R: A Language and Environment for Statistical. Computing_","year":"2023"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7056","article-title":"Global burden, risk factors, and trends of non\u2010Hodgkin lymphoma: A worldwide analysis of cancer registries","volume":"13","author":"Huang","year":"2024","journal-title":"Cancer Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11899-024-00727-w","article-title":"Update on T-cell lymphoma epidemiology","volume":"19","author":"Chen","year":"2024","journal-title":"Curr Hematol Malig Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.148809","article-title":"Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project","volume":"101","author":"Perry","year":"2016","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1182\/blood-2023-187254","article-title":"Epidemiology, clinical features and outcomes of peripheral T-cell lymphoma in latin america","volume":"142","author":"Fischer","year":"2023","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5540","article-title":"Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States","volume":"34","author":"Adams","year":"2016","journal-title":"JCO"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061414","article-title":"EBV and the pathogenesis of NK\/T cell lymphoma","volume":"13","author":"Montes-Mojarro","year":"2021","journal-title":"Cancers"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.584254","article-title":"Classification of non-Hodgkin lymphomas in Guatemala according to the World Health Organization system","volume":"52","author":"Perry","year":"2011","journal-title":"Leukemia Lymphoma"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.654471","article-title":"Non-Hodgkin lymphoma in Chile: a review of 207 consecutive adult cases by a panel of five expert hematopathologists","volume":"53","author":"Cabrera","year":"2012","journal-title":"Leukemia Lymphoma"},{"key":"B29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.gde.2016.06.016","article-title":"A genomic view of the peopling of the Americas","volume":"41","author":"Skoglund","year":"2016","journal-title":"Curr Opin Genet Dev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2016.09.003","article-title":"Admixture in latin america","volume":"41","author":"Adhikari","year":"2016","journal-title":"Curr Opin Genet Dev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00171-6","article-title":"Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study","volume":"11","author":"Herrera","year":"2024","journal-title":"Lancet Haematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-821009","article-title":"Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas","volume":"131","author":"Fanale","year":"2018","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S189825","article-title":"Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis","volume":"12","author":"Deng","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030589","article-title":"Therapeutic advances in relapsed and refractory peripheral T-cell lymphoma","volume":"15","author":"Stuver","year":"2023","journal-title":"Cancers"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092332","article-title":"Peripheral T-cell lymphomas: therapeutic approaches","volume":"14","author":"Sibon","year":"2022","journal-title":"Cancers"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3960\/jslrt.22034","article-title":"Prognostic indices for peripheral T-cell lymphoma - not otherwise specified and adult T-cell leukemia\/lymphoma: From past to future","volume":"63","author":"Ishitsuka","year":"2023","journal-title":"JCEH"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6004\/jadpro.2024.15.8.3","article-title":"Peripheral T-cell lymphoma, not otherwise specified: diagnosis and therapeutic approaches for the advanced practice provider","volume":"15","author":"Ow","year":"2024","journal-title":"JADPRO"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1898102\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:34:39Z","timestamp":1785299679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1898102\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":38,"alternative-id":["10.3389\/fonc.2026.1898102"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1898102","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1898102"}}